logo-loader
/**/ h1{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:9.85pt;margin-bottom:.0001pt;text-align:justify;text-autospace:none;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight:bold;}h2{margin-top:.05pt;margin-right:0cm;margin-bottom:0cm;margin-left:5.85pt;margin-bottom:.0001pt;text-align:justify;text-autospace:none;font-size:12.0pt;font-family:"Calibri Light","sans-serif";font-weight:normal;}h3{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:5.85pt;margin-bottom:.0001pt;text-align:justify;text-autospace:none;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight:bold;}p{margin-right:0cm;margin-left:0cm;font-size:11.0pt;font-family:"Calibri","sans-serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: #0563C1 }visited{ color: #954F72 } .aa{size:595.0pt 842.5pt;margin:68.05pt 62.35pt 2.0cm 62.35pt;}div.aa{}p.bd{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:0cm;margin-right:2.5pt;margin-bottom:12.0pt; margin-left:0cm}span.bb{font-size:16.0pt;font-family:"Calibri Light","sans-serif"; color:#234060}p.be{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-right:2.5pt}span.az{font-size:16.0pt;font-family:"Calibri Light","sans-serif";color:#234060}p.bf{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align:justify}p.bg{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align:justify;line-height:112%}span.aw{color:#171717}span.au{font-size:10.0pt;line-height:112%;font-family:"Arial","sans-serif"; color:black} p.bh{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; margin-left: 5.85pt; text-align: justify}span.at{color:black}p.bi{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:.4pt;margin-right:0cm;margin-bottom:0cm; margin-left:5.85pt;margin-bottom:.0001pt}span.ar{font-size:10.0pt; color:black}table.bj{width:460.7pt;margin-left:3.4pt;border-collapse:collapse}tr.al{height:34.15pt}td.an{width:312.5pt;padding:0cm 5.4pt 0cm 5.4pt; height:34.15pt}p.bk{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; margin-bottom: 0cm; margin-left: 5.85pt; margin-right: 4.75pt; margin-top: 0cm; text-align: justify}p.bl{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:0cm;margin-right:4.75pt;margin-bottom: 0cm;margin-left:5.85pt;margin-bottom:.0001pt;text-align:justify}td.am{width:126.6pt;padding:0cm 5.4pt 0cm 5.4pt; height:34.15pt} tr.ah{height:26.15pt}td.aj{width:312.5pt;padding:0cm 5.4pt 0cm 5.4pt; height:26.15pt}p.bm{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-left:5.85pt}td.ai{width:126.6pt;padding:0cm 5.4pt 0cm 5.4pt; height:26.15pt}td.ag{width:312.5pt;padding:0cm 5.4pt 0cm 5.4pt}td.af{width:126.6pt;padding:0cm 5.4pt 0cm 5.4pt}p.bn{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:.4pt}span.ad{font-size: 10.0pt;font-family:"Arial","sans-serif"}p.bo{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; text-align: justify} /**/
RNS Number : 3664D
Silence Therapeutics PLC
25 June 2019
 

Result of AGM

June 25, 2019

 

 

LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the Company") a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, announces that at its Annual General Meeting held today, all resolutions were duly passed.

 

  

 

 

Enquiries:

 

Silence Therapeutics plc

Dr David Horn Solomon, Chief Executive Officer

 

 

Tel:  +44 (0)20 3457 6900

Peel Hunt LLP (Nominated Adviser and Broker)

James Steel/Oliver Jackson

 

Tel:  +44 (0)20 7418 8900

European IR

Consilium Strategic Communications

Mary-Jane Elliott/Chris Welsh/Angela Gray

[email protected]

 

Tel: +44 (0) 20 3709 5700

US IR

Westwicke Partners

Peter Vozzo

[email protected]

 

 Tel: +1 (443) 213-0505

 

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural

mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively

inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using

its enabling delivery systems, it has achieved an additional level of specificity by delivering its

therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and

delivery systems are designed to improve the stability of our molecules and enhance effective delivery

to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

For more information, please visit: https://www.silence-therapeutics.com/ 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
RAGSELFFIFUSESM

Quick facts: Silence Therapeutics PLC

Price: 396

Market: AIM
Market Cap: £310.22 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Silence Therapeutics 'charging ahead with its key...

David Solomon, chief executive of Silence Therapeutics PLC (LON:SLN), updates on developments across their three key programmes - SLN 500, 124 and 360. Discussing the firm's current valuation, Solomon says ''there's a lot more steam in the engine''. ''I think that's what's exciting - we're...

3 weeks, 1 day ago